TGN-1062

While there are some successful treatments, like use of cetuximab in patients with EGFR expressing tumors, there is still a major unmet need in this area. Targeting CDK7 with TGN-1062 in combination with SOC therapy is a promising approach for treatment of HNSCC. TGN-1062 is a potent CDK7 inhibitor with potential for clinical development.

Our potent and selective small molecule inhibitor of CDK7, TGN-1062, shows promise in pancreatic cancer models as a single or in combination with SOC . Preliminary data suggests that TGN-1062 can be developed further in multiple cancer indications.

TGN-1062 is a novel, selective, and reversible inhibitor of CDK7 and has significant antitumor activity in vivo. TGN-1062 is a potent CDK7 inhibitor with potential for clinical development.